NCT02256436View on ClinicalTrials.gov

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

PHASE3CompletedINTERVENTIONAL

Enrollment

542

Participants

Timeline

Start Date

October 22, 2014

Primary Completion Date

September 7, 2016

Study Completion Date

October 1, 2020

Conditions

Urothelial Cancer

Interventions

BIOLOGICAL

pembrolizumab

IV infusion

DRUG

paclitaxel

IV infusion

DRUG

vinflunine

IV infusion

DRUG

docetaxel

IV infusion

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02256436 - A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | Biotech Hunter | Biotech Hunter